Enhancing antidepressant safety surveillance: comparative analysis of adverse drug reaction signals in spontaneous reporting and healthcare claims databases

被引:1
|
作者
Kim, Taehyung [1 ,2 ]
Jiang, Xinying [3 ,4 ]
Noh, Youran [1 ,2 ]
Kim, Maryanne [1 ,2 ]
Hong, Song Hee [1 ,2 ]
机构
[1] Seoul Natl Univ, Colleage Pharm, Seoul, South Korea
[2] Seoul Natl Univ, Res Inst Pharmaceut Sci, Coll Pharm, Seoul, South Korea
[3] Healthcare & Life Sci China, Shanghai, Peoples R China
[4] Renaissance Grp, Shanghai, Peoples R China
基金
新加坡国家研究基金会;
关键词
signal detection; drug safety surveillance; spontaneous reporting system; healthcare claim database; antidepressant; adverse drug reaction; pharmacovigilance; LARGE FREQUENCY TABLES; PERFORMANCE; SYSTEMS;
D O I
10.3389/fphar.2023.1291934
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background/Objective: Spontaneous reporting systems (SRS) such as the Korea Adverse Event Reporting System (KAERS) are limited in their ability to detect adverse drug reaction (ADR) signals due to their limited data on drug use. Conversely, the national health insurance claim (NHIC) data include drug use information for all qualifying residents. This study aimed to compare ADR signal profiles for antidepressants between KAERS and NHIC, evaluating the extent to which detected signals belong to common ADRs and labeling information.Materials and Methods: ADR signal detection in KAERS and NHIC databases, spanning January to December 2017, employed disproportionality analysis. Signal classes were determined based on System Organ Class (SOC) of the Medical Dictionary for Regulatory Activities (MedDRA). Also, Common ADR Coverage (CAC), the proportion of detected signals deemed common ADRs, and labeling information coverage (LIC) represented by mean average precision (mAP) were calculated. Additionally, protopathic bias and relative risk (RR) evaluation were performed to check for signal robustness.Results: Signal detection revealed 51 and 62 signals in KAERS and NHIC databases, respectively. Both systems predominantly captured signals related to nervous system disorders, comprising 33.3% (N = 17) in KAERS and 50.8% (N = 31) in NHIC. Regarding the type of antidepressants, KAERS predominantly reported signals associated with tricyclic antidepressants (TCAs) (N = 21, 41.2%), while NHIC produced most signals linked to selective serotonin reuptake inhibitors (SSRIs) (N = 22, 35.5%). KAERS exhibited higher CAC (68.63% vs. 29.03%) than NHIC. LIC was also higher in KAERS than in NHIC (mAP for EB05: 1.00 vs. 0.983); i.e., NHIC identified 5 signals not documented in drug labeling information, while KAERS found none. Among the unlabeled signals, one (Duloxetine-Myelopathy) was from protopathic bias, and two (duloxetine-myelopathy and tianeptine-osteomalacia) were statistically significant in RR.Conclusion: NHIC exhibited greater capability in detecting ADR signals associated with antidepressant use, encompassing unlabeled ADR signals, compared to KAERS. NHIC also demonstrated greater potential for identifying less common ADRs. Further investigation is needed for signals detected exclusively in NHIC but not covered by labeling information. This study underscores the value of integrating different sources of data, offering substantial regulatory insights and enriching the scope of pharmacovigilance.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Is Pegylation of Drugs Associated to Hypersensitivity Reactions? An Analysis of The Italian National Spontaneous Adverse Drug Reaction Reporting System
    Crisafulli, S.
    Cutroneo, P. M.
    Luxi, N.
    Fontana, A.
    Ferrajolo, C.
    Marchione, P.
    Sottosanti, L.
    Zanoni, G.
    Moretti, U.
    Franze, S.
    Minghetti, P.
    Trifiro, G.
    DRUG SAFETY, 2022, 45 (10) : 1316 - 1316
  • [32] The Quality of Clinical Information in Adverse Drug Reaction Reports by Patients and Healthcare Professionals: A Retrospective Comparative Analysis
    Leàn Rolfes
    Florence van Hunsel
    Laura van der Linden
    Katja Taxis
    Eugène van Puijenbroek
    Drug Safety, 2017, 40 : 607 - 614
  • [33] The Quality of Clinical Information in Adverse Drug Reaction Reports by Patients and Healthcare Professionals: A Retrospective Comparative Analysis
    Rolfes, Lean
    van Hunsel, Florence
    van der Linden, Laura
    Taxis, Katja
    van Puijenbroek, Eugene
    DRUG SAFETY, 2017, 40 (07) : 607 - 614
  • [34] Cancer in Patients Exposed to anti-TNF: Analysis of the French Spontaneous Reporting Database for a Controversial Adverse Drug Reaction
    Saliba, L.
    Aboutaam, M.
    Rousseau, V.
    Chebane, L.
    Petitpain, N.
    Baldin, B.
    Gillet, P.
    Montastruc, J. L.
    Bagheri, H.
    DRUG SAFETY, 2013, 36 (09) : 807 - 807
  • [35] Healthcare professionals' awareness, attitudes and practices towards pharmacovigilance and spontaneous adverse drug reaction reporting in Jazan Province, Saudi Arabia: A survey study
    Alqahtani, Saad S.
    Ahmad, Sarfaraz
    Alam, Nawazish
    Syed, Nabeel Kashan
    Syed, Mamoon H.
    Khardali, Amani
    Yasmeen, Ayesha
    Alshahrani, Ali M.
    Alzarea, Abdulaziz, I
    Alanazi, Abdullah S.
    Elnaem, Mohamed Hassan
    SAUDI PHARMACEUTICAL JOURNAL, 2023, 31 (06) : 979 - 988
  • [36] Safety of combined drug use in patients with cardiovascular and cerebrovascular diseases: an analysis based on the spontaneous reporting database of adverse drug reactions in Hubei Province
    Wang, Jia
    Zhao, Yuhang
    Chen, Zherui
    Huang, Rui
    FRONTIERS IN PHARMACOLOGY, 2025, 15
  • [37] Safety profiles of methylphenidate, amphetamine, and atomoxetine: analysis of spontaneous reports submitted to the food and drug administration adverse event reporting system
    Wei, Wei
    Chen, Li
    Zhou, Hui
    Liu, Jinfeng
    Zhang, Yue
    Feng, Shiyu
    Bai, Yingtao
    Leng, Yanen
    Chang, En
    Huang, Liang
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [38] New Insight on the Safety of Erenumab: An Analysis of Spontaneous Reports of Adverse Events Recorded in the US Food and Drug Administration Adverse Event Reporting System Database
    Maurizio Sessa
    Morten Andersen
    BioDrugs, 2021, 35 : 215 - 227
  • [39] New Insight on the Safety of Erenumab: An Analysis of Spontaneous Reports of Adverse Events Recorded in the US Food and Drug Administration Adverse Event Reporting System Database
    Sessa, Maurizio
    Andersen, Morten
    BIODRUGS, 2021, 35 (02) : 215 - 227
  • [40] Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system
    Chen, Jiao-Jiao
    Huo, Xue-Chen
    Wang, Shao-Xia
    Wang, Fei
    Zhao, Quan
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2022, 44 (06) : 1351 - 1360